Omar H. Fahmy
Hoppe Seyler Street 3
Tuebingen, BW 72076, Germany
Tuebingen, BW 72076, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Correction: Fahmy et al. Optimized Icariin Cubosomes Exhibit Augmented Cytotoxicity against SKOV-3 Ovarian Cancer Cells. Pharmaceutics 2021, 13, 20.
Journal: Pharmaceutics
Published: January 10, 2025
Retraction Note: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer.
Journal: Scientific reports
Published: November 13, 2024
Photodynamic Therapy: Current Trends and Potential Future Role in the Treatment of Bladder Cancer.
Journal: International journal of molecular sciences
Published: October 13, 2023
Practice change: No benefit of extended lymphadenectomy at radical cystectomy in patients with muscle invasive bladder cancer.
Journal: Seminars in oncology
Published: August 29, 2023
New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer.
Journal: Bladder cancer (Amsterdam, Netherlands)
Published: May 31, 2023
Role of inguinal and pelvic lymph node dissection for primary urethral carcinoma: a systematic review.
Journal: Current opinion in urology
Published: May 09, 2023
Guillain-Barré Syndrome following intravesical Bacillus Calmette-Guérin therapy for bladder cancer: a rare and intriguing case report.
Journal: Central European journal of urology
Published: April 24, 2023
A rare case of bladder leiomyoma in pregnancy: a case report
Journal: Urologiia (Moscow, Russia : 1999)
Published: January 10, 2023
2-Methoxyestradiol TPGS Micelles Attenuate Cyclosporine A-Induced Nephrotoxicity in Rats through Inhibition of TGF-β1 and p-ERK1/2 Axis.
Journal: Antioxidants (Basel, Switzerland)
Published: July 17, 2022
Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer.
Journal: Scientific reports
Published: May 09, 2022
Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis.
Journal: Biomedicines
Published: March 20, 2022
Last Updated: 09/26/2026